## Additional file 1: Table S1

| Characteristics | No. | $\%$ |
| :--- | :---: | :---: |
| No. of patients | 73 | 100 |

Age

| $\geq 60$ | 25 | 34.25 |
| :--- | :--- | :--- |
| $<60$ | 48 | 65.75 |

Gender

| Female | 22 | 30.14 |
| :---: | :--- | :--- |
| Male | 51 | 69.86 |

Histology
Non-squamous 49
Squamous 24
67.12
32.88

Smoking

| Never | 37 | 50.68 |
| :---: | :---: | :---: |
| Ever | 6 | 8.22 |
| Current | 30 | 41.10 |

Ecog

| 0 | 18 | 24.66 |
| :--- | :--- | :--- |
| 1 | 55 | 75.34 |

Metastasis
Metastasic sites $\geq 326$
35.62

Metastasic sites <3 47
64.38

LDH

$$
\begin{array}{lll}
\geq 250 \mathrm{U} / \mathrm{L} & 34 & 46.58 \\
<250 \mathrm{U} / \mathrm{L} & 39 & 53.42
\end{array}
$$

Treatment
Anti-PD1 54
73.97

Anti-PD-L1 19
19.00

Lines of therapy
Second 39
Third or subsequent 34
53.42
46.58

PD-L1 expression

| $<1 \%$ | 35 | 47.95 |
| :---: | :---: | :---: |
| $1-49 \%$ | 11 | 15.07 |
| $>50 \%$ | 3 | 4.11 |
| unknown | 23 | 31.51 |

Best overall response

| CR | 1 | 1.37 |
| :---: | :---: | :---: |
| PR | 13 | 17.81 |
| SD | 19 | 26.03 |
| PD | 40 | 54.79 |

Driver mutation

| EGFR | 9 | 12.33 |
| :---: | :---: | :---: |
| KRAS | 7 | 9.59 |
| TP53 | 36 | 49.32 |

TMB

| $\geq 10$ | 18 | 24.66 |
| :--- | :--- | :--- |
| $<10$ | 55 | 75.34 |

Additional file 1: Table S2.Details of 8 NSCLC cohorts analyzed in this study.

| cohort | cases | sequencing | source | drugs | PFS | OS | responses |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| NCC | 73 | WES | tissue | anti-PD-(L)1 | yes | NA | ORR |
| N.Rizvi | $34^{*}$ | WES | tissue | anti-PD-1 | yes | NA | ORR |
| Miao | 56 | WES | tissue | anti-PD-(L)1 <br> +anti-CTLA-4 | yes | yes | ORR |
| Hellmann | 75 | WES | tissue | anti-PD-(L)1 | yes | NA | ORR |
| MSKCC-240 | 240 | IMAPCT <br> 341/410/468 | tissue | anti-PD-(L)1 | yes | NA | DCB |
| MSKCC-350 | 350 | IMPACT <br> $341 / 410 / 468$ | tissue | anti-PD-(L)1 | NA | yes | NA |
| OAK | 408 | Foundation One | ctDNA | anti-PD-L1 | yes | yes | ORR |
| POPLAR | 134 | Foundation One | ctDNA | anti-PD-L1 | yes | yes | ORR |

Note: 28 patients with PFS data were shared by N.Rizvi cohort and Miao cohort. Hence, when analyzing PFS, these 2 cohorts were merged as Miao \& N.Rizvi cohort. Besides, MSKCC-240 and MSKCC-350 also shared some patients, but MSKCC-240 cohort only contained PFS data while MSKCCCK-350 only contained PFS data. So, MSKCC-240 and MSKCC-350 cohort were still analyzed separately.

Additional file 1: Table S3.


Additional file 1: Table S4.

| NAME | SIZE | ES | NES | NOM p -value | FDR q-value | FWER p -value |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HALLMARK_UV_RESPONSE_DN | 134 | -0.424 | -1.359 | 0.031 | 0.376 | 0.469 |
| HALLMARK_HEDGEHOG_SIGNALING | 34 | -0.476 | -1.421 | 0.047 | 0.432 | 0.339 |
| HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | 194 | -0.565 | -1.273 | 0.092 | 0.522 | 0.601 |
| HALLMARK_MYOGENESIS | 199 | -0.323 | -1.264 | 0.094 | 0.420 | 0.616 |
| HALLMARK_INTERFERON_ALPHA_RESPONSE | 90 | 0.501 | 1.405 | 0.113 | 0.663 | 0.349 |
| HALLMARK_OXIDATIVE_PHOSPHORYLATION | 179 | 0.530 | 1.260 | 0.129 | 1.000 | 0.597 |
| HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | 45 | -0.474 | -1.163 | 0.209 | 0.684 | 0.696 |
| HALLMARK_KRAS_SIGNALING_DN | 188 | 0.172 | 1.130 | 0.218 | 1.000 | 0.716 |
| HALLMARK_PANCREAS_BETA_CELLS | 38 | 0.346 | 1.210 | 0.228 | 1.000 | 0.651 |
| HALLMARK_PEROXISOME | 100 | 0.309 | 1.099 | 0.268 | 0.901 | 0.750 |
| HALLMARK_MYC_TARGETS_V2 | 57 | 0.418 | 1.177 | 0.274 | 0.996 | 0.679 |
| HALLMARK_DNA_REPAIR | 138 | 0.387 | 1.128 | 0.284 | 0.896 | 0.718 |
| HALLMARK_MITOTIC_SPINDLE | 194 | -0.297 | -1.118 | 0.346 | 0.742 | 0.733 |
| HALLMARK_INTERFERON_GAMMA_RESPONSE | 190 | 0.356 | 1.083 | 0.374 | 0.856 | 0.768 |
| HALLMARK_IL6_JAK_STAT3_SIGNALING | 86 | 0.391 | 1.063 | 0.381 | 0.841 | 0.789 |
| HALLMARK_SPERMATOGENESIS | 130 | 0.144 | 1.024 | 0.415 | 0.899 | 0.827 |
| HALLMARK_XENOBIOTIC_METABOLISM | 198 | -0.280 | -1.027 | 0.422 | 0.995 | 0.811 |
| HALLMARK_MYC_TARGETS_V1 | 189 | 0.478 | 1.010 | 0.464 | 0.873 | 0.838 |
| HALLMARK_PROTEIN_SECRETION | 95 | -0.338 | -1.002 | 0.469 | 0.972 | 0.834 |
| HALLMARK_E2F_TARGETS | 186 | 0.345 | 0.963 | 0.507 | 0.893 | 0.874 |
| HALLMARK_ANGIOGENESIS | 36 | -0.416 | -0.976 | 0.525 | 0.960 | 0.863 |
| HALLMARK_ALLOGRAFT_REJECTION | 189 | 0.340 | 0.975 | 0.530 | 0.921 | 0.863 |
| HALLMARK_HYPOXIA | 188 | -0.329 | -0.974 | 0.538 | 0.871 | 0.863 |
| HALLMARK_HEME_METABOLISM | 187 | -0.198 | -0.945 | 0.592 | 0.890 | 0.887 |
| HALLMARK_TNFA_SIGNALING_VIA_NFKB | 194 | 0.339 | 0.913 | 0.632 | 0.773 | 0.912 |
| HALLMARK_UV_RESPONSE_UP | 152 | 0.341 | 0.944 | 0.640 | 0.890 | 0.884 |
| HALLMARK_PI3K_AKT_MTOR_SIGNALING | 101 | 0.289 | 0.929 | 0.642 | 0.822 | 0.901 |
| HALLMARK_ADIPOGENESIS | 185 | 0.267 | 0.925 | 0.654 | 0.786 | 0.905 |
| HALLMARK_COMPLEMENT | 193 | 0.268 | 0.898 | 0.656 | 0.771 | 0.918 |
| HALLMARK_ESTROGEN_RESPONSE_LATE | 196 | 0.298 | 0.938 | 0.683 | 0.852 | 0.895 |
| HALLMARK_APICAL_JUNCTION | 193 | -0.263 | -0.879 | 0.702 | 1.000 | 0.922 |
| HALLMARK_P53_PATHWAY | 193 | 0.277 | 0.896 | 0.720 | 0.737 | 0.918 |
| HALLMARK_CHOLESTEROL_HOMEOSTASIS | 73 | -0.297 | -0.855 | 0.738 | 0.947 | 0.940 |
| HALLMARK_COAGULATION | 136 | -0.260 | -0.861 | 0.759 | 0.999 | 0.936 |
| HALLMARK_TGF_BETA_SIGNALING | 54 | -0.306 | -0.837 | 0.764 | 0.876 | 0.951 |
| HALLMARK_FATTY_ACID_METABOLISM | 155 | -0.260 | -0.837 | 0.794 | 0.934 | 0.951 |
| HALLMARK_G2M_CHECKPOINT | 183 | 0.281 | 0.721 | 0.835 | 0.952 | 0.992 |
| HALLMARK_NOTC̄H_SIGNALING | 32 | 0.263 | 0.794 | 0.842 | 0.967 | 0.970 |
| HALLMARK_GLYCOLYSIS | 192 | -0.249 | -0.810 | 0.860 | 0.895 | 0.961 |
| HALLMARK_ESTROGEN_RESPONSE_EARLY | 190 | -0.216 | -0.806 | 0.863 | 0.855 | 0.961 |
| HALLMARK_IL2_STAT5_SIGNALING | 190 | -0.207 | -0.786 | 0.864 | 0.859 | 0.967 |
| HALLMARK_UNFOLDED_PROTEIN_RESPONSE | 108 | 0.257 | 0.791 | 0.877 | 0.933 | 0.973 |
| HALLMARK_MTORC1_SIGNALING | 194 | -0.306 | -0.769 | 0.882 | 0.853 | 0.973 |
| HALLMARK_BILE_ACID_METABOLISM | 112 | 0.139 | 0.781 | 0.885 | 0.919 | 0.979 |
| HALLMARK_APICAL_SURFACE | 42 | 0.168 | 0.762 | 0.896 | 0.930 | 0.986 |
| HALLMARK_WNT_BETA_CATENIN_SIGNALING | 42 | -0.243 | -0.721 | 0.917 | 0.871 | 0.985 |
| HALLMARK_ANDROGEN_RESPONSE | 95 | -0.240 | -0.764 | 0.922 | 0.823 | 0.974 |
| HALLMARK_INFLAMMATORY_RESPONSE | 197 | 0.229 | 0.719 | 0.923 | 0.918 | 0.992 |
| HALLMARK_KRAS_SIGNALING_UP | 194 | 0.193 | 0.711 | 0.980 | 0.899 | 0.992 |
| HALLMARK_APOPTOSIS | 159 | 0.291 | 0.758 | 0.982 | 0.903 | 0.986 |
| KEGG_TGF_BETA_SIGNALING_PATHWAY | 85 | -0.243 | -0.786 | 0.873 | 0.931 | 1.000 |
| KEGG_WNT_SIGNALING_PATHWAY | 149 | -0.221 | -0.905 | 0.639 | 0.937 | 1.000 |
| KEGG_VEGF_SIGNALING_PATHWAY | 74 | 0.220 | 0.841 | 0.746 | 1.000 | 1.000 |

